Recent advances in therapeutic apheresis

Journal of Artificial Organs

Volumn 6, Issue 1, 2003, Pages 1-8

  Bosch, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Apheresis; Immunoadsorption; Macular degeneration; Rheopheresis; Sudden hearing loss

Indexed keywords

ALBUMINOID; CD4 ANTIGEN; ENDOTOXIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; SILICON DIOXIDE; STAPHYLOCOCCUS PROTEIN A;

ADSORPTION; APHERESIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLOOD RHEOLOGY; CLINICAL TRIAL; DIRECT ADSORPTION OF LIPIDS LOW DENSITY LIPOPROTEIN APHERESIS; DOUBLE FILTRATION PLASMAPHERESIS; ENDOTOXIN ADSORBER STUDY APHERESIS; HEARING LOSS; HEART DILATATION; HEPARIN INDUCED EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION APHERESIS; HUMAN; IMMUNOADSORPTION; INTERMETHOD COMPARISON; KIDNEY GRAFT REJECTION; LOW DENSITY LIPOPROTEIN APHERESIS; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEOPHERESIS; RHEUMATOID ARTHRITIS; SAFETY; SEPSIS; TREATMENT INDICATION;

ARTHRITIS, RHEUMATOID; BLOOD COMPONENT REMOVAL; CARDIOMYOPATHY, DILATED; CLINICAL TRIALS; GRAFT REJECTION; HEARING LOSS; HUMANS; HYPERLIPIDEMIAS; KIDNEY TRANSPLANTATION; MACULAR DEGENERATION; SEPSIS;

EID: 0038672078     PISSN: 14347229     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100470300000     Document Type: Review

References (41)

1. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002;347:589-600
2. Suckfüll M. Heparin-induced low-density lipoprotein precipitation apheresis: a new therapeutic concept in the treatment of sudden hearing loss. Ther Apheresis 2001;5:377-383
3. Suckfüll M. Hyperfibrinogenemia as a risk factor for sudden hearing loss. Otol Neurotol 2002;23:309-311
4. Eisenhauer T, Schuff-Werner P, Armstrong VW, Müller U, Bosch T, Thiery J, Gurland HJ, Seidel D. Simultaneous heparin-induced extracorporeal LDL precipitation and haemodialysis: first clinical experience. Trans Am Soc Artif Intern Organs 1991;37:M494-M496
5. Schuff-Werner P, Schütz E, Seyde WC, Eisenhauer T, Janning G, Armstrong VW, Seidel D. Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989;19:30-37
6. Suckfüll M. Fibrinogen and LDL apheresis in treatment of sudden hearing loss: a randomized multicenter trail. Lancet 2002;360:1811-1817
7. Schütt F, Holz FG. Age-related macular degeneration: current concepts of pathogenesis and risk factors. In: Alberti WE, Richard G, Sagermann RH (eds) Age-related macular degeneration. Berlin: Springer, 2001;3-9
8. Klingel R, Fassbender C, Fischer I, Hattenbach L, Gümbel H, Pulido J, Koch F. Rheopheresis for age-related macular degeneration: a novel indication for therapeutic apheresis in ophthalmology. Ther Apheresis 2002;6:271-281
9. Nakaji S, Yamamoto T. Membranes for therapeutic apheresis. Ther Apheresis 2002;6:267-270
10. Sueoka A. Therapeutic apheresis application using membrane plasma fractionation technology: present scope and limitations. Ther Apheresis 2000;4:211-212
11. Brunner R, Widder RA, Walter P, Borberg H, Oette K. Change in hemorheological and biochemical parameters following membrane differential filtration. Int J Artif Org 1995;18:794-798
12. Klingel R, Fassbender C, Fassbender T, Erdtracht B, Berrouschot J. Rheopheresis: rheologic, functional and structural aspects. Ther Apheresis 4:348-357
13. Lipsky PE. Rheumatoid arthritis. In: Braunwald E (ed) Harrison's principles of internal medicine, 15th edn. New York: McGraw Hill, 2001;1928-1936
14. Feldmann M, Maini RM. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-196
15. Braun N, Bosch T. Immunoadsorption, current status and future developments. Exp Opin Invest Drugs 2000;9:2017-2038
16. Felson DT, LaValley MP, Baldassare AR, Block JA, Caldwell JR, Cannon GW, Deal C, Evans S, Fleischmann R, Gendreau RM, Harris ER, Matteson EL, Roth SH, Schumacher HR, Weisman MH, Furst DE. The Prosorba column for treatment of refractory rheumatoid arthritis. Arthritis Rheum 1999;42:2153-2159
17. Gendreau RM. A randomized double-blind sham-controlled trial of the Prosorba column for treatment of refractory rheumatoid arthritis. Ther Apheresis 2001;5:79-83
18. Sasso EH, Merrill C, Furst TE. Immunoglobulin binding properties of the Prosorba immunoadsorption column in treatment of rheumatoid arthritis. Ther Apheresis 2001;5:84-91
19. Felix SB, Staudt A, Dörffel WV, Stangl V, Merkel K, Pohl M, Döcke WD, Morgera S, Neumayer HH, Wernecke KD, Wallukat G, Stangl K, Baumann G. Haemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy. J Am Coll Cardiol 2000;35:1590-1598
20. Staudt A, Schäper F, Stangl V, Plagemann A, Böhm M, Merkel K, Wallukat G, Wernecke K, Stangl K, Baumann G, Felix SB. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001;103:2681-2686
21. Felix SB, Staudt A, Landsberger M, Grosse Y, Stangl V, Spielhagen T, Wallukat G, Wernicke KD, Baumann G, Stangl K. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002;39:646-652
22. Böhmig GA, Exner M, Habicht A, Schillinger M, Lang U, Kletzmayr J, Säemann MD, Hörl WH, Watschinger B, Regele H. Capillary C4d depostion in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-1099
23. Regele H, Böhmig GA, Habicht A, Gollowitzer D, Schillinger M, Rockenschaub S, Watschinger B, Kerjaschki D, Exner M. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002;13:2371-2380
24. Böhmig GH, Regele H, Exner M, Derhartunian V, Kletzmayr J, Säemann MD, Hörl W, Drummel W, Watschinger B. C4d-positive acute humoral renal allograft rejection: effect of treatment by immunoadsorption. J Am Soc Nephrol 2001;12:2482-2489
25. Werdan K. Pathophysiology of septic shock and multiple organ dysfunction syndrome and various therapeutic approches with special emphasis on immunoglobulins. Ther Apheresis 2001;5:115-122
26. Zimmermann M, Busch K, Kuhn S, Zeppezauer M. Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med 1999;37:373-379
27. Ullrich H, Jakob W, Fröhlich D, Rothe G, Prasser C, Drobnik W, Taeger K, Meier-Hellmann A, Reinhart K, Zimmermann M, Schmitz G. A new endotoxin adsorber: first clinical application. Ther Apheresis 2001;5:326-334
28. Staubach K. Whole blood adsorption of endotoxins in sepsis: the Matisse multicenter study. 9th Congress of the World Apheresis Association, Paris, 7-10 September 2002
29. Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995;332:512-521
30. Ballantyne CM, Herd JA, Dunn JK, Jones PH, Farmer JA, Gotto AM. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol 1997;8:354-361
31. Bosch T. State of the art of lipid apheresis. Artif Organs 1996;20:292-295
32. Susca M. Heparin-induced extracorporeal low-density lipoprotein precipitation Futura, a new modification of HELP apheresis: technique and first clinical results. Ther Apheresis 2001;5:387-393
33. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: in vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif Organs 1993;17:640-652
34. Bosch T, Lennertz A, Schenzle D, Dräger J, for the DALI Study Group. Direct adsorption of low-density lipoprotein and lipoprotein(a) from whole blood: results of the first clinical long-term multicenter study using DALI apheresis. J Clin Apheresis 2002;17:161-169
35. Bosch T, Lennertz A, Samtleben W. High-efficiency DALI apheresis using 1250ml adsorbers in a hypercholesterolemic obese patient: a case report. Ther Apheresis 2001;5:358-363
36. Bosch T, Schilling R, Sodemann K, for the DALI Study Group. Efficacy and safety of DALI LDL apheresis at high blood flow rates - a multicenter study. 9th Congress of the World Apheresis Association, Paris, 7-10 September 2002, Abstract Book p 65
37. Gordon BR, Kelsey SF, Dau PC, Gotto AM Jr, Graham K, Illingworth R, Isaacsohn J, Jones PH, Leitman SF, Saal SD, Stein EA, Stern TN, Troendle A, Zwiener RJ. Long-term effects of LDL apheresis using an automated dextransulfate cellulose adsorption system. Am J Cardiol 1998;81:407-411
38. Kobayashi A, Nakatani M, Furuyoshi S, Tani N. In-vitro evaluation of dextran sulfate cellulose beads for whole blood infusion low-density lipoprotein hemoperfusion. Ther Apheresis 2002;6:365-371
39. Atassi-Dumont M, Trémesi PJ, Zribi H, Bruckert E, Moulin PH. Kaneka direct hemoperfusion system comparison with DALI: preliminary results. 9th Congress of the World Apheresis Association, Paris, 7-10 September 2002, Abstract Book p 35
40. Klinkmann H. Therapeutic use of adsorption technologies: the gap between reality and possibility. 9th Congress of the World Apheresis Association, Paris, 7-10 September 2002
41. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972;18:499-502